妇女绝经期与下尿路症状中西医诊疗的研究进展

doi:10.3969/j.issn.1006-7795.2024.05.020

摘要/Abstract

摘要： 下尿路功能障碍（lower urinary tract dysfunctions, LUTD）是绝经期泌尿生殖系统综合征（genitourinary syndrome of menopause, GSM）症状中的关键问题，主要是由女性绝经后体内雌激素水平降低、泌尿生殖道结构改变、炎症反应、微生态菌群变化引起，严重影响女性生活质量。LUTD治疗涉及中西医防治及健康监测，其中阴道局部低雌激素用药是目前治疗的核心，任何单一药物不能替代。在诊疗过程中更要注重对GSM的综合、个体化、总体健康情况把控及长期管理。本文主要综述妇女绝经期与下尿路症状中西医诊疗的研究进展。

关键词: 绝经期, 绝经期泌尿生殖系统综合征, 下尿路功能障碍, 激素治疗, 电针技术

Abstract: Lower urinary tract dysfunction (LUTD) is a key problem for patients with genitourinary syndrome of menopause (GSM). LUTD is mainly caused by low estrogen levels, urogenital atrophy, urinary tract infections and alterations in the vaginal microbiota. These symptoms adversely affect many aspects of a woman's daily life. LUTD treatment involves traditional Chinese and Western medicine prevention and health monitoring. Vaginal low estrogen in the treatment of LUTD is the mainstay of medical treatment which is a key comprehensive, individualized and synergistic therapeutic approach to restore urogenital physiology. This review describes the research progress of menopause and Chinese and Western medicine treatment for LUTD.

Key words: menopause, genitourinary syndrome of menopause, lower urinary tract dysfunctions, hormone treatment, electroacupuncture

中图分类号:

赵越, 张泉东. 妇女绝经期与下尿路症状中西医诊疗的研究进展[J]. 首都医科大学学报, 2024, 45(5): 875-880.

Zhao Yue, Zhang Quandong. Chinese and Western medicine treatment for lower urinary tract dysfunctions in postmenopausal women: a systematic review[J]. Journal of Capital Medical University, 2024, 45(5): 875-880.

参考文献

［1］Jahangirifar M, Fooladi E, Davis S R, et al. Menopause symptoms, sexual dysfunctions and pelvic floor disorders in refugee and asylum seeker women: a scoping review［J］. Climacteric, 2023, 26(4): 373－380.
［2］Peinado-Molina R A, Hernández-Martínez A, Martínez-Vázquez S, et al. Pelvic floor dysfunction: prevalence and associated factors［J］. BMC Public Health, 2023, 23(1): 2005.
［3］Filippini M, Biordi N, Curcio A, et al. A qualitative and quantitative study to evaluate the effectiveness and safety of magnetic stimulation in women with urinary incontinence symptoms and pelvic floor disorders［J］. Medicina, 2023, 59(5): 879.
［4］Mori da Cunha M G M C, Mackova K, Hympanova L H, et al. Animal models for pelvic organ prolapse: systematic review［J］. Int Urogynecol J, 2021, 32(6): 1331－1344.
［5］Sammarco A G, Sheyn D D, Krantz T E, et al. A novel measurement of pelvic floor cross-sectional area in older and younger women with and without prolapse［J］. Am J Obstet Gynecol, 2019, 221(5): 521.e1－521.e7.
［6］Crandall C J, Mehta J M, Manson J E. Management of menopausal symptoms: a review［J］. JAMA, 2023, 329(5): 405－420.
［7］Valadares A, Kulak J J, Paiva L, et al. Genitourinary syndrome of menopause［J］. Rev Bras Ginecol Obstet, 2022, 44(3): 319－324.
［8］van Geelen H, Sand P K. The female urethra: urethral function throughout a woman's lifetime［J］. Int Urogynecol J, 2023, 34(6): 1175－1186.
［9］Clark A L, Goetsch M F. Genitourinary syndrome of menopause: pathophysiology, clinical presentation, and differential diagnosis［J］. Clin Obstet Gynecol, 2024, 67(1): 13－26.
［10］Bodner-Adler B, Alarab M, Ruiz-Zapata A M, et al. Effectiveness of hormones in postmenopausal pelvic floor dysfunction-International Urogynecological Association research and development-committee opinion［J］. Int Urogynecol J, 2020, 31(8): 1577－1582.
［11］Dietz H P, Socha M, Atan I K, et al. Does estrogen deprivation affect pelvic floor muscle contractility?［J］. Int Urogynecol J, 2020, 31(1): 191－196.
［12］Sipos A G, Kozma B, Poka R, et al. The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: pelvic floor distress inventory-20 questionnaire［J］. Lasers Surg Med, 2019, 51(10): 882－886.
［13］Carter A E, Merriam S. Menopause［J］. Med Clin North Am, 2023, 107(2): 199－212.
［14］Sarmento A C A, Costa A P F, Vieira-Baptista P, et al. Genitourinary syndrome of menopause: epidemiology, physiopathology, clinical manifestation and diagnostic［J］. Front Reprod Health, 2021, 3: 779398.
［15］Tomoe H, Ozaki Y, Yamamoto M, et al. Epidemiological study of genitourinary syndrome of menopause in Japan (GENJA study)［J］. Menopause, 2023, 30(4): 447－453.
［16］La Rosa V L, Ciebiera M, Lin L T, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function［J］. Prz Menopauzalny, 2019, 18(2): 116－122.
［17］Christmas M M, Iyer S, Daisy C, et al. Menopause hormone therapy and urinary symptoms: a systematic review［J］. Menopause, 2023, 30(6): 672－685.
［18］Bapir R, Bhatti K H, Eliwa A, et al. Treatment of urge incontinence in postmenopausal women: a systematic review［J］. Arch Ital Urol Androl, 2023, 95(3): 11718.
［19］Jang Y C, Leung C Y, Huang H L. Comparison of severity of genitourinary syndrome of menopause symptoms after carbon dioxide laser vs vaginal estrogen therapy: a systematic review and meta-analysis［J］. JAMA Netw Open, 2022, 5(9): e2232563.
［20］Trémollieres F, Chabbert-Buffet N, Plu-Bureau G, et al. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (short version)［J］. Gynecol Obstet Fertil Senol, 2021, 49(5): 305－317.
［21］Cox S, Nasseri R, Rubin R S, et al. Genitourinary syndrome of menopause［J］. Med Clin North Am, 2023, 107(2): 357－369.
［22］Pitsouni E, Grigoriadis T, Falagas M E, et al. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis［J］. Maturitas, 2017, 103: 78－88.
［23］Nemirovsky A, Villela N A, Yuan J C, et al. Vaginal hormone therapy for conditions of the lower urinary tract［J］. Curr Urol Rep, 2023, 24(2): 41－50.
［24］Bhattacharya S, Singal A K, Kalra S. The endocrinology of the urinary bladder［J］. J Pak Med Assoc, 2023, 73(12): 2488－2490.
［25］Benini V, Ruffolo A F, Casiraghi A, et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review［J］. Medicina, 2022, 58(6): 770.
［26］Park M G, Cho S, Oh M M. Menopausal changes in the microbiome-a review focused on the genitourinary microbiome［J］. Diagnostics, 2023, 13(6): 1193.
［27］Pérez-López F R, Fernández-Alonso A M, Mezones-Holguín E, et al. Low genitourinary tract risks in women living with the human immunodeficiency virus［J］. Climacteric, 2023, 26(4): 316－322.
［28］Rahn D D, Richter H E, Sung V W, et al. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse［J］. Am J Obstet Gynecol, 2023, 229(3): 309.e1－309.e10.
［29］Andreeva E N, Sheremetyeva E V. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women［J］. Probl Endokrinol, 2022, 68(6): 157－163.
［30］Patil A. Response to “a comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females”［J］. Indian J Pharmacol, 2020, 52(6): 524－525.
［31］Ligon M M, Joshi C S, Fashemi B E, et al. Effects of aging on urinary tract epithelial homeostasis and immunity［J］. Dev Biol, 2023, 493: 29－39.
［32］Hardy C C, Korstanje R. Aging and urinary control: alterations in the brain-bladder axis［J］. Aging Cell, 2023, 22(12): e13990.
［33］Wasnik V B, Acharya N, Mohammad S. Genitourinary syndrome of menopause: a narrative review focusing on its effects on the sexual health and quality of life of women［J］. Cureus, 2023, 15(11): e48143.
［34］Wu C, Newman D, Schwartz T A, et al. Effects of unsupervised behavioral and pelvic floor muscle training programs on nocturia, urinary urgency, and urinary frequency in postmenopausal women: secondary analysis of a randomized, two-arm, parallel design, superiority trial (TULIP study)［J］. Maturitas, 2021, 146: 42－48.
［35］ElSheikh M A, Atia A A, Metwaly N S, et al. Influence of self-care guidelines on improving menopausal urogenital symptoms［J］. J Pak Med Assoc, 2023, 73(suppl 4)(4): S210-S214.
［36］Biscola N P, Bartmeyer P M, Christe K L, et al. Detrusor underactivity is associated with metabolic syndrome in aged primates［J］. Sci Rep, 2023, 13(1): 6716.
［37］Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review［J］. Ann Clin Microbiol Antimicrob, 2020, 19(1): 5.
［38］Alvisi S, Ceccarani C, Foschi C, et al. Effect of ospemifene on vaginal microbiome in postmenopausal women with vulvovaginal atrophy［J］. Menopause, 2023, 30(4): 361－369.
［39］Stabile G, Topouzova G A, De S F. The role of microbiota in the management of genitourinary syndrome of menopause［J］. Climacteric, 2023, 26(4): 353－360.
［40］Yoshikata R M, Yamaguchi M, Mase Y R, et al. Age-related changes, influencing factors, and crosstalk between vaginal and gut microbiota: a cross-sectional comparative study of pre- and postmenopausal women［J］. J Womens Health, 2022, 31(12): 1763－1772.
［41］Lumsden M A, Davies M, Sarri G. Diagnosis and management of menopause: the national institute of health and care excellence (NICE) guideline［J］. JAMA Intern Med，2016，176(8):1205-1206.
［42］Van Gerwen O T, Smith S E, Muzny C A. Bacterial vaginosis in postmenopausal women［J］. Curr Infect Dis Rep, 2023, 25(1): 7－15.
［43］Chen Q, Wang H J, Wang G, et al. Lactic acid bacteria: a promising tool for menopausal health management in women［J］. Nutrients, 2022, 14(21): 4466.
［44］Dothard M I, Allard S M, Gilbert J A. The effects of hormone replacement therapy on the microbiomes of postmenopausal women［J］. Climacteric, 2023, 26(3): 182－192.
［45］Musbahi E, Kamp E, Ashraf M, et al. Menopause,skin and common dermatosis. Part 3: genital disorders［J］. Clin Exp Dermatol, 2022, 47(12): 2123－2129.
［46］Waetjen L E, Crawford S L, Gajer P, et al. Relationships between the vaginal microbiota and genitourinary syndrome of menopause symptoms in postmenopausal women: the Study of Womens Health Across the Nation［J］. Menopause, 2023, 30(11): 1073－1084.
［47］Micks E, Reed S D, Mitchell C. The postmenopausal vaginal microbiome and genitourinary syndrome of menopause［J］. Clin Obstet Gynecol, 2024, 67(1): 79－88.
［48］Lebeer S, Ahannach S, Gehrmann T, et al. A citizen-science-enabled catalogue of the vaginal microbiome and associated factors［J］. Nat Microbiol, 2023, 8(11): 2183－2195.
［49］de Oliveira N S, de Lima A B F, de Brito J C R, et al. Postmenopausal vaginal microbiome and microbiota［J］. Front Reprod Health, 2021, 3: 780931.
［50］Jongjakapun A, Somboonporn W, Temtanakitpaisan T. Effectiveness of vaginal estriol with lactobacilli on urinary symptoms in postmenopausal women: a randomized-controlled trial［J］. Menopause, 2023, 30(4): 441－446.
［51］Fashemi B E, Wang C H, Chappidi R R, et al. Supraphysiologic vaginal estrogen therapy in aged mice mitigates age-associated bladder inflammatory response to urinary tract infections［J］. Urogynecology, 2023, 29(4): 430－442.
［52］Abou-Taleb H A, Fathalla Z, Naguib D M, et al. Chitosan/solid-lipid nanoparticles hybrid gels for vaginal delivery of estradiol for management of vaginal menopausal symptoms［J］. Pharmaceuticals (Basel), 2023, 16(9): 1284.
［53］Suskind A M, Quanstrom K, Zhao S J, et al. Overactive bladder is strongly associated with frailty in older individuals［J］. Urology, 2017, 106: 26－31.
［54］Cao Y, Zhang H, Tang X H, et al. Alterations in the balance of sex hormones may affect rat prostatic inflammation and fibrosis, and osteopontin might be involved in this process［J］. Int Urol Nephrol, 2023, 55(9): 2355－2365.
［55］Wein A J. Re:overactive bladder is strongly associated with frailty in older individuals［J］. J Urol, 2018, 199(5): 29677910.
［56］Burt E, Davies M C, Yasmin E, et al. Reduced uterine volume after induction of puberty in women with hypogonadism［J］. Clin Endocrinol, 2019, 91(6): 798－804.
［57］Kuno T, Tamura K, Shimizu N, et al. Vibegron 50 mg once daily improves OABSS, OAB-q SF score in OAB patients ≥80 years old in real-world clinical settings and switching from other OAB drugs may reduce residual urine volume［J］. Res Rep Urol, 2023, 15: 157－164.
［58］Shen J W, Luo R, Zhang L, et al. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: a case report［J］. Medicine, 2019, 98(45): e17795.
［59］沈建武, 罗然, 孟军, 等. 电针疗法治疗女性膀胱过度活动症的临床研究［J］. 中国中西医结合杂志, 2020, 40(8): 1000－1004.
［60］Zhang P, Zhang Y G, Liao L M, et al. Application of Internet+-based Tsinghua PINS Remote Tech to improve sacral neuromodulation programming procedure［J］. Int Urol Nephrol, 2019, 51(4): 627－632.

[1]	关毅鸣, 刁宗礼, 黄红东, 刘文虎. 反复静脉钙刺激对慢性肾衰竭大鼠血管钙化的影响[J]. 首都医科大学学报, 2024, 45(5): 823-830.
[2]	陈香慧, 贾婷, 杨莹, 李艳, 魏世卓, 王佳琪, 冯莹莹, 马芳霞, 陈钊, 王莉, 付荣国. 尿蛋白/肌酐比与24-h尿蛋白定量在肾小球疾病尿蛋白水平测量中的一致性评价[J]. 首都医科大学学报, 2024, 45(5): 831-837.
[3]	秦云龙, 周瑾, 刘萌, 罗开发, 王安静, 王頔, 赵晋, 孙世仁. 恶性高血压肾硬化的临床病理特征及预后分析[J]. 首都医科大学学报, 2024, 45(5): 838-845.
[4]	靳琼, 董德鑫, 赵越, 耿宇宁. 宫颈癌保留神经手术后排尿功能评价[J]. 首都医科大学学报, 2024, 45(5): 853-857.
[5]	闫伟, 向鹏, 谢英伟, 郑宇朋, 平浩. 一次性输尿管软镜治疗肾盂旁囊肿合并同侧继发肾结石[J]. 首都医科大学学报, 2024, 45(5): 858-863.
[6]	张泉东, 刘辉. 复杂肾结石一期手术中应用被动可弯负压吸引鞘的效果观察[J]. 首都医科大学学报, 2024, 45(5): 864-869.
[7]	张大坤, 张洪波, 董德鑫, 高翔, 郑瀚, 张浪. 上尿路结石行输尿管镜碎石术后尿源性脓毒血症的早期诊治[J]. 首都医科大学学报, 2024, 45(5): 870-874.
[8]	白雨, 田东丽. 腺苷1型受体在肾脏疾病中的研究进展[J]. 首都医科大学学报, 2024, 45(3): 543-547.
[9]	封怡多, 黄琪, 周亦伦 . 慢性肾脏病患者认知功能状况及危险因素[J]. 首都医科大学学报, 2023, 44(5): 788-794.
[10]	徐潇漪, 王国勤, 程虹, 赵智睿, 董鸿瑞, 孙丽君. 小剂量利妥昔单抗治疗特发性膜性肾病的疗效及其影响因素[J]. 首都医科大学学报, 2022, 43(5): 680-686.
[11]	赵纬昊, 张亚妮, 李柯, 姚恬, 景兰梅, 霍雨佳, 马小琴, 王欣, 刘静, 马晓桃, 付荣国, 田李芳. 超声引导下经皮肾穿刺活检后出血的危险因素[J]. 首都医科大学学报, 2022, 43(5): 694-699.
[12]	马晓桃, 张亚妮, 崔晨凯, 郭昭, 郭萌, 石玥, 吴瑶, 赵莉, 刘静, 赵纬昊, 付荣国, 田李芳. 不同病理类型及组织特点对肾活检后出血的影响[J]. 首都医科大学学报, 2022, 43(5): 700-706.
[13]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[14]	郭康林, 程一春, 葛树旺, 徐钢. IgA肾病国际风险预测工具在中国人群中的预测效果评价[J]. 首都医科大学学报, 2022, 43(5): 713-719.
[15]	陈晓媚, 马圆媛, 聂静, 朱风新. 急性肾损伤向慢性肾脏病转化中肾小管上皮细胞损伤修复机制的研究进展[J]. 首都医科大学学报, 2022, 43(5): 720-727.